TLRY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TLRY is not a good buy right now for a beginner long-term investor with $50,000-$100,000 and an impatient style. The stock has some positive catalysts, but the technical trend is still weak, Wall Street is mixed, and there is no strong proprietary buy signal. My direct view is to hold off rather than buy now.
Current price is $5.015, down 1.95% in regular trading, with a small pre-market gain of 0.20%. Momentum is mixed: MACD histogram is positive and expanding, but RSI at 44.4 is neutral and not showing strong upside strength. The bigger issue is trend structure: SMA_200 > SMA_20 > SMA_5 is bearish, meaning the stock is still trading below a stronger long-term recovery structure. Price is below the pivot at 5.232 and only slightly above support at 4.926, so near-term downside remains possible. The pattern-based outlook also points to weakness over the next day, week, and month.
["Tilray launched the ARX medical cannabis brand in Germany, expanding its premium medical cannabis presence in Europe.", "The Germany launch is supported by distribution partnerships with CC Pharma and 14U Pharma, which improves reach.", "BrewDog partnership to launch 24 American craft beers in the UK strengthens brand visibility in Europe.", "Retail sentiment has remained relatively bullish, with the stock up 26% over the past year."]
["Canaccord cut its price target to C$9.50 from C$13 and kept Hold.", "Alliance Global cut its target to $7 from $9 and kept Neutral after weak sales versus estimates and hemp restriction uncertainty.", "TD Cowen cut its target to $7 from $10 despite keeping Buy, citing lower EBITDA estimates and cost pressure.", "Tilray faces pricing pressure as a wholesale manufacturer compared with retail-focused peers.", "Similar candlestick pattern analysis suggests downside over the next day, week, and month.", "No AI Stock Picker or SwingMax buy signal is present today."]
Latest quarter financials were not fully provided, but the news summary says Tilray's fiscal Q3 sales came in below estimates while EBITDA beat due to savings initiatives. That suggests cost control is helping, but top-line growth is still not strong enough to create a convincing long-term fundamental case yet. The company is also dealing with pricing pressure and uncertainty around hemp restrictions, while beverage cost pressures remain a concern.
Analyst sentiment is mixed to slightly cautious. Recent changes show several price target cuts: Canaccord to C$9.50, Alliance Global to $7, and TD Cowen to $7. One bullish change stands out: Roth Capital upgraded Tilray to Buy with a $10 target, citing steady Canadian business, improving international operations, and better beverage trends. Overall, Wall Street is split, but the balance of recent target cuts makes the view more cautious than optimistic.
